Galderma Group AG

Fr 191.75As of Sun 8 Nov 2026, 12:00 UTC
SWX:GALDHealthcare
Country Switzerland
PE (Fwd) •••
TSR 3Y CAGR 54.21%
Div yield 0.18%
ROE 10.82%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) (0.11)
PE TTM 64.97
TSR TTM 31.70%
Mkt cap Fr 44.71B
ROIC 10.28%
SE Grade™
Value
Quality
Moat
Consensus
Reference
Fr 223
16.21%
(64.45%)
Hold 1|12|12|10|0
4Q25
1Q26
2Q26
3Q26
Earnings per share$
2.43
2.36
2.35
2.36
24.14%
19.31%
10.78%
1.89%
Revenue$B
3.091
3.093
3.262
3.335
11.21%
5.46%
8.71%
12.48%
Peers (US$54.84B)
Cap (US$)
PE
308.2B
30.48x
44.46B
70.61x
3.868B
18.46x
49.80B
37.66x
Capital
TTM
5Y
10Y
Leveragex
1.387
0.287
0.287
EBIT/Intx
0.919
0.927
0.649
Own earn%
(52.87)
12.70
7.18
Sh yield%
31.78
48.24
47.82
Owners
Insiders/Inst%
9.84
67.10
Short interest%
3.87
SBC / revenue%
2.29
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
15–23
$1 testx
—
Incr. ROIC%
6

Galderma Group AG is a dermatology company operating worldwide that delivers a science-based portfolio of brands and services for the dermatology market across injectable aesthetics, dermatological skincare and therapeutic dermatology. Its flagship brands include Azzalure, ALLUZIENCE, Dysport, Restylane, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac and Loceryl.